RecruitingPhase 1Phase 2NCT04982276

A Study of AK109 and AK104 in Advanced Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma

A Multicentre, Phase Ib/II Clinical Study of AK109 and AK104 With or Without Chemotherapy in Second-line Treatment of Advanced Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma

Sponsor

Akeso

Enrollment

138 participants

Start Date

Aug 23, 2021

Study Type

INTERVENTIONAL

Conditions

Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma

Summary

This is a multicentre, Phase Ib/II Clinical Study of AK109 and AK104 With or Without Chemotherapy in Second-line Treatment of Advanced Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma .

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called AK104, a biological treatment called AK109, and others for people with gastric adenocarcinoma and gastroesophageal junction adenocarcinoma. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years to 75 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALAK109

Subjects will receive AK109 by intravenous administration.

DRUGpaclitaxel

Subjects will receive AK109 in combination with paclitaxel.

DRUGpaclitaxel

Subjects will receive AK104 and AK109 in combination with paclitaxel.

BIOLOGICALAK104

Subjects will receive AK104 by intravenous administration.

Locations(1)

Beijing Cancer Hospital

Beijing, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT04982276

Related Trials

SHR-1701 Combined With Chemotherapy for Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis

NCT073842342 locations

Phase II RAINSPOT: Zolbetuximab-Paclitaxel-Ramucirumab for CLDN18.2 Positive Gastro-esophageal Cancer

NCT069621376 locations